Johnson & Johnson

Johnson & Johnson's CARVYKTI cell therapy significantly improved overall survival in Phase III CARTITUDE-4 trial for multiple myeloma patients, reducing mortality risk by 45% compared to standard therapies.

Formycon and Fresenius Kabi announce FDA approval of FYB202/OtulfiTM (ustekinumab-aauz), a biosimilar to Stelara®, for treating Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis. This marks Formycon’s third successful FDA approval for a biosimilar, with Fresenius Kabi set to market OtulfiTM in the US by February 2025.

Johnson & Johnson's RedirecTT-1 study shows high response rates and durable responses with Talvey and Tecvayli bispecific antibody combination in relapsed or refractory multiple myeloma patients, including those with extramedullary disease, with a consistent safety profile. The overall response rate was 79.5%, with a complete response or better rate of 52.3%.

The European Commission approves Yuvanci®, a single tablet combination therapy for PAH, marking the first such option in Europe. This approval is based on the Phase 3 A DUE study, which showed significant reductions in pulmonary vascular resistance compared to individual monotherapies. Yuvanci® addresses the unmet need for simplified PAH treatment regimens, aligning with ESC/ERS guidelines.

Updated RedirecTT-1 study results show high response rates and durable responses with a consistent safety profile for talquetamab and teclistamab combination in relapsed or refractory multiple myeloma patients, presented at the 2024 IMS Annual Meeting.

Focused ultrasound, backed by Hong Kong tycoon Li Ka-shing, is gaining recognition as a commercially attractive alternative to traditional therapies for diseases like cancer. The growth in treatments, clinical trials, and investments indicates its scaling up, with HistoSonics, a focused ultrasound device maker, attracting significant investments. The Li Ka Shing Foundation has donated devices to the University of Hong Kong and plans further donations to support treatment and training.

Johnson & Johnson's Phase 1b RedirecTT-1 study shows high response rates and durable responses with a consistent safety profile for the combination of TALVEY and TECVAYLI in triple-class exposed, relapsed or refractory multiple myeloma patients, including those with extramedullary disease.

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.

MP Nigdelis received honoraria from RG Ärztefortbildung GmbH and travel grants from Organon and Gedeon Richter. M Doerk received travel grants from Gedeon Richter, Organon, and Eisai, and is a member of DGGG, AGE, and Deutsche Gesellschaft für Senologie. S Burghaus received honoraria from FOMF and is a member of DGGG, AGEM, AGE, Stiftung Endometriose Forschung, AGUB, AGO, and DKK. M Sillem, CEO of EuroEndoCert Gmbh, received payments from Bayer, Gedeon Richter, Hologic, and EndoHealth. B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca, Johnson & Johnson, and Storz, and is a member of DGGG, AGE, and Stiftung Endometriose Forschung. EF Solomayer receives grants from the University of Saarland, Storz, and Erbe, and fees from Roche, Pfizer, Celgene, Amgen, Astra Zeneca, Esai, Johnson & Johnson, Novartis, Tesaro, Teva, Medac GmbH, MSD, Vifor, Gedeon Richter, Takeda, and AGE, among others. GL Olmes received grants from AstraZeneca, Universitätsklinikum Freiburg, and RG Ärztefortbildung GmbH, and is a member of DGGG, AGE, and AGEM, with scientific collaboration with Karl Stotz.